Discovery and Subsequent Characterization of Potent 4R-Tauopathy Positron Emission Tomography Radiotracers

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2023 Jul 24

PMID 37487189

Authors

Thomas J A Graham

Anton Lindberg

Junchao Tong

Jeffrey S Stehouwer

Neil Vasdev

Robert H Mach

Chester A Mathis

Affiliations

Soon will be listed here.

Abstract

A chemical fingerprint search identified Z3777013540 (1-(5-(6-fluoro-1-indol-2-yl)pyrimidin-2-yl)piperidin-4-ol; ) as a potential 4R-tau binding ligand. Binding assays in post-mortem Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD) brain with [H] provided (nM) values in AD = 4.0, PSP = 5.1, and CBD = 4.5. positron emission tomography (PET) imaging in rats with [F] demonstrated good brain penetration and rapid clearance from normal brain tissues. A subsequent molecular similarity search using as the query revealed an additional promising compound, Z4169252340 (4-(5-(6-fluoro-1-indol-2-yl)pyrimidin-2-yl)morpholine; ). Binding assays with [H] provided (nM) values in AD = 1.2, PSP = 1.6, and CBD = 1.7 and lower affinities for binding aggregated α-synuclein and amyloid-beta. PET imaging in rats with [F] demonstrated a higher brain penetration than [F] and rapid clearance from normal brain tissues. We anticipate that and will be useful for the identification of other potent novel 4R-tau radiotracers.

Citing Articles

F-MK-6240 tau PET in patients at-risk for chronic traumatic encephalopathy.

Alosco M, Mejia Perez J, Culhane J, Shankar R, Nowinski C, Bureau S Mol Neurodegener. 2025; 20(1):23.

PMID: 39994806 PMC: 11852567. DOI: 10.1186/s13024-025-00808-1.

Strategies of positron emission tomography (PET) tracer development for imaging of tau and α-synuclein in neurodegenerative disorders.

Mekala S, Wu Y, Li Y RSC Med Chem. 2024; .

PMID: 39678127 PMC: 11638850. DOI: 10.1039/d4md00576g.

Ligand-based design of [F]OXD-2314 for PET imaging in non-Alzheimer's disease tauopathies.

Lindberg A, Murrell E, Tong J, Mason N, Sohn D, Sandell J Nat Commun. 2024; 15(1):5109.

PMID: 38877019 PMC: 11178805. DOI: 10.1038/s41467-024-49258-1.

Diagnostic and Therapeutic Radiopharmaceuticals: A "Hot" Topic.

Lindsley C, Muller C, Bongarzone S ACS Pharmacol Transl Sci. 2024; 7(1):1-7.

PMID: 38230278 PMC: 10789131. DOI: 10.1021/acsptsci.3c00347.

Insight into the Binding of First- and Second-Generation PET Tracers to 4R and 3R/4R Tau Protofibrils.

Li J, Kumar A, Langstrom B, Nordberg A, Agren H ACS Chem Neurosci. 2023; 14(18):3528-3539.

PMID: 37639522 PMC: 10515481. DOI: 10.1021/acschemneuro.3c00437.

References

Xia C, Arteaga J, Chen G, Gangadharmath U, Gomez L, Kasi D . [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement. 2013; 9(6):666-76. DOI: 10.1016/j.jalz.2012.11.008. View

Tezuka T, Takahata K, Seki M, Tabuchi H, Momota Y, Shiraiwa M . Evaluation of [F]PI-2620, a second-generation selective tau tracer, for assessing four-repeat tauopathies. Brain Commun. 2021; 3(4):fcab190. PMC: 8495135. DOI: 10.1093/braincomms/fcab190. View

Palleis C, Brendel M, Finze A, Weidinger E, Botzel K, Danek A . Cortical [ F]PI-2620 Binding Differentiates Corticobasal Syndrome Subtypes. Mov Disord. 2021; 36(9):2104-2115. DOI: 10.1002/mds.28624. View

Goedert M, Eisenberg D, Crowther R . Propagation of Tau Aggregates and Neurodegeneration. Annu Rev Neurosci. 2017; 40:189-210. DOI: 10.1146/annurev-neuro-072116-031153. View

Kroth H, Oden F, Serra A, Molette J, Mueller A, Berndt M . Structure-activity relationship around PI-2620 highlights the importance of the nitrogen atom position in the tricyclic core. Bioorg Med Chem. 2021; 52:116528. DOI: 10.1016/j.bmc.2021.116528. View

Falcon B, Zhang W, Schweighauser M, Murzin A, Vidal R, Garringer H . Tau filaments from multiple cases of sporadic and inherited Alzheimer's disease adopt a common fold. Acta Neuropathol. 2018; 136(5):699-708. PMC: 6208733. DOI: 10.1007/s00401-018-1914-z. View

Schwarz A, Danckaert A, Reese T, Gozzi A, Paxinos G, Watson C . A stereotaxic MRI template set for the rat brain with tissue class distribution maps and co-registered anatomical atlas: application to pharmacological MRI. Neuroimage. 2006; 32(2):538-50. DOI: 10.1016/j.neuroimage.2006.04.214. View

Gupta M, Lee H, Barden C, Weaver D . The Blood-Brain Barrier (BBB) Score. J Med Chem. 2019; 62(21):9824-9836. DOI: 10.1021/acs.jmedchem.9b01220. View

Zischler J, Kolks N, Modemann D, Neumaier B, Zlatopolskiy B . Alcohol-Enhanced Cu-Mediated Radiofluorination. Chemistry. 2016; 23(14):3251-3256. DOI: 10.1002/chem.201604633. View

10.

Zhang W, Tarutani A, Newell K, Murzin A, Matsubara T, Falcon B . Novel tau filament fold in corticobasal degeneration. Nature. 2020; 580(7802):283-287. PMC: 7148158. DOI: 10.1038/s41586-020-2043-0. View

11.

Kinahan P, Fletcher J . Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR. 2010; 31(6):496-505. PMC: 3026294. DOI: 10.1053/j.sult.2010.10.001. View

12.

Marquie M, Normandin M, Meltzer A, Siao Tick Chong M, Andrea N, Anton-Fernandez A . Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol. 2016; 81(1):117-128. PMC: 5319193. DOI: 10.1002/ana.24844. View

13.

Gogola A, Minhas D, Villemagne V, Cohen A, Mountz J, Pascoal T . Direct Comparison of the Tau PET Tracers F-Flortaucipir and F-MK-6240 in Human Subjects. J Nucl Med. 2021; 63(1):108-116. PMC: 8717175. DOI: 10.2967/jnumed.120.254961. View

14.

Aguero C, Dhaynaut M, Normandin M, Amaral A, Guehl N, Neelamegam R . Autoradiography validation of novel tau PET tracer [F-18]-MK-6240 on human postmortem brain tissue. Acta Neuropathol Commun. 2019; 7(1):37. PMC: 6410510. DOI: 10.1186/s40478-019-0686-6. View

15.

Berriman J, Serpell L, Oberg K, Fink A, Goedert M, Crowther R . Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A. 2003; 100(15):9034-8. PMC: 166433. DOI: 10.1073/pnas.1530287100. View

16.

Cho H, Choi J, Lee H, Lee J, Ryu Y, Lee M . Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. J Nucl Med. 2019; 60(11):1611-1621. PMC: 6836867. DOI: 10.2967/jnumed.118.221697. View

17.

Li L, Liu F, Li M, Lu J, Sun Y, Liang X . Clinical Utility of F-APN-1607 Tau PET Imaging in Patients with Progressive Supranuclear Palsy. Mov Disord. 2021; 36(10):2314-2323. DOI: 10.1002/mds.28672. View

18.

Kawamura K, Hashimoto H, Furutsuka K, Ohkubo T, Fujishiro T, Togashi T . Radiosynthesis and quality control testing of the tau imaging positron emission tomography tracer [ F]PM-PBB3 for clinical applications. J Labelled Comp Radiopharm. 2020; 64(3):109-119. DOI: 10.1002/jlcr.3890. View

19.

Brendel M, Barthel H, van Eimeren T, Marek K, Beyer L, Song M . Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurol. 2020; 77(11):1408-1419. PMC: 7341407. DOI: 10.1001/jamaneurol.2020.2526. View

20.

Falcon B, Zhang W, Murzin A, Murshudov G, Garringer H, Vidal R . Structures of filaments from Pick's disease reveal a novel tau protein fold. Nature. 2018; 561(7721):137-140. PMC: 6204212. DOI: 10.1038/s41586-018-0454-y. View